These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 38326371

  • 1. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
    Bose M, Sanders A, Handa A, Vora A, Cardona MR, Brouwer C, Mukherjee P.
    Sci Rep; 2024 Feb 07; 14(1):3178. PubMed ID: 38326371
    [Abstract] [Full Text] [Related]

  • 2. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM, Grothey A.
    Drugs; 2017 Jul 07; 77(10):1091-1103. PubMed ID: 28573435
    [Abstract] [Full Text] [Related]

  • 3. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y, Peng X, Li H, Jiao W, Peng X, Shao J, Xu Y, Wang R, Wang W, Kong D.
    Recent Pat Anticancer Drug Discov; 2021 Jul 07; 16(3):350-362. PubMed ID: 33655847
    [Abstract] [Full Text] [Related]

  • 4. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
    Shao Z, Wang H, Ren H, Sun Y, Chen X.
    Molecules; 2023 Jul 27; 28(15):. PubMed ID: 37570646
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH, Määttä J, Linder A, Sterbova S, Ohlsson C, Damber JE, Widmark A, Persson E.
    Prostate; 2021 Jun 27; 81(8):452-462. PubMed ID: 33822400
    [Abstract] [Full Text] [Related]

  • 6. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Li X, Wei Y, Wei X.
    Cancer Lett; 2020 Oct 28; 491():146-161. PubMed ID: 32798587
    [Abstract] [Full Text] [Related]

  • 7. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
    Li C, Chen C, An Q, Yang T, Sang Z, Yang Y, Ju Y, Tong A, Luo Y.
    Eur J Med Chem; 2019 Jan 15; 162():543-554. PubMed ID: 30472602
    [Abstract] [Full Text] [Related]

  • 8. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
    Han D, Yu T, Dong N, Wang B, Sun F, Jiang D.
    J Exp Clin Cancer Res; 2019 Jul 05; 38(1):289. PubMed ID: 31277685
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H, Clamor C, Müller K.
    J Nat Prod; 2018 Jul 27; 81(7):1636-1644. PubMed ID: 30003778
    [Abstract] [Full Text] [Related]

  • 12. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism.
    Leijten NM, Bakker P, Spaink HP, den Hertog J, Lemeer S.
    Mol Cell Proteomics; 2021 Jul 27; 20():100033. PubMed ID: 33594990
    [Abstract] [Full Text] [Related]

  • 13. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.
    Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB.
    Int J Oncol; 2009 Aug 27; 35(2):337-45. PubMed ID: 19578748
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
    Chang AY, Hsu E, Patel J, Li Y, Zhang M, Iguchi H, Rogoff HA.
    Mol Cancer Res; 2019 Jul 27; 17(7):1429-1434. PubMed ID: 31043490
    [Abstract] [Full Text] [Related]

  • 15. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
    Froeling FEM, Swamynathan MM, Deschênes A, Chio IIC, Brosnan E, Yao MA, Alagesan P, Lucito M, Li J, Chang AY, Trotman LC, Belleau P, Park Y, Rogoff HA, Watson JD, Tuveson DA.
    Clin Cancer Res; 2019 Dec 01; 25(23):7162-7174. PubMed ID: 31527169
    [Abstract] [Full Text] [Related]

  • 16. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
    Wang YT, Tang F, Hu X, Zheng CX, Gong TJ, Zhou Y, Luo Y, Min L.
    IUBMB Life; 2020 Oct 01; 72(10):2146-2153. PubMed ID: 33448097
    [Abstract] [Full Text] [Related]

  • 17. MUC1: a multifaceted oncoprotein with a key role in cancer progression.
    Nath S, Mukherjee P.
    Trends Mol Med; 2014 Jun 01; 20(6):332-42. PubMed ID: 24667139
    [Abstract] [Full Text] [Related]

  • 18. Genetic regulation of MUC1 expression by Helicobacter pylori in gastric cancer cells.
    Guang W, Czinn SJ, Blanchard TG, Kim KC, Lillehoj EP.
    Biochem Biophys Res Commun; 2014 Feb 28; 445(1):145-50. PubMed ID: 24491543
    [Abstract] [Full Text] [Related]

  • 19. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
    Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ.
    Lancet Gastroenterol Hepatol; 2018 Apr 28; 3(4):263-270. PubMed ID: 29397354
    [Abstract] [Full Text] [Related]

  • 20. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism.
    Zhao C, Li H, Lin HJ, Yang S, Lin J, Liang G.
    Trends Pharmacol Sci; 2016 Jan 28; 37(1):47-61. PubMed ID: 26576830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.